Kidney Failure Research indicates that in some cases, use of semaglutide contributes to kidney disease
Eric Xu, Li-Hua Zhao, Dehua Yang & Ming-Wei Wang Source : This study utilized cryo-electron microscopy to elucidate the structural basis of Retatrutides triple agonism at the GLP-1, GIP, and GCG receptors
People on retatrutide in clinical trials experienced a decrease in total body fat mass by as much as 26.1%, while others lost up to 6.5 kg of lean mass
Additionally, follow-up at 31 weeks showed no difference in eGFR between the placebo and oral-semaglutide groups compared with baseline eGFR measurements, suggesting that treatment had no adverse effects on kidney function
doi: 10.1016/j.jbc.2021.101388
Alternatively, participants could also be enrolled if they were aged 60 years or older and had cardiovascular risk factors